Traditional and classic methods of therapeutic effects at the dorsopathies

10.12737/5033 ◽  
2014 ◽  
Vol 8 (1) ◽  
pp. 1-6
Author(s):  
Чигарев ◽  
A. Chigarev ◽  
Шилов ◽  
A. Shilov ◽  
Агасаров ◽  
...  

Dorsopathies are enduring importance among medical problems. This confirms the fact that the World Health Organization declared a theme associated with dorsopathies, as priorities for the next five-year period. It should be emphasized that the etiology and pathogenesis of these states are reviewed with the «enviable» frequency, and this, naturally, is reflected on the principles of treatment and rehabilitation of this contingent. In this review the mechanisms and features of application of the basic drug and non-drug methods of treatment used in modern clinic, are considered. It should be noted that a use of a complex approach, aimed at correction and relief of various vertebral and pathological manifestations, is optimal in this case. In particular, the review presents in details the options for medical treatment and a variety of technologies of physical stimulation - from traction to modern hardware methods of physiotherapy. Taking into account authors’ own original developments, special attention is paid to theoretical and practical aspects of reflexology, which is widely used in complex therapy of patients with dorsopathies. In this block, the authors provide Oriental, traditional approaches to acupuncture and promising ways, based on the combined use of Eastern and Western medical schemes. The authors identify separately the pharmacopuncture as the action caused by the summation of the effects as reflex irritation and entered in the field point of medicaments. Pharmacopuncture involves the use of various medicines, but complex homeopathic remedies provide a distinct therapeutic result, i.e., the authors suggest that there are subtle mechanisms of interaction between point and drugs of this class.

2015 ◽  
Vol 9 (1) ◽  
pp. 0-0
Author(s):  
Агасаров ◽  
L. Agasarov ◽  
Кузьмина ◽  
I. Kuzmina ◽  
Чигарев ◽  
...  

The World Health Organization declared the problems of dorsopathies (vertebrogenic syndromes) as priorities for the next five-year period. The key questions of etiology and pathogenesis of dorsopathies for the last period has been revised, which affects the principles of treatment and rehabilitation of this category of patients. This article highlights the main clinical and pathogenetic characteristics of the process. A diagnostic algorithm, mechanisms of action and therapeutic possibilities of the main methods of correction are considered. Also the article considers the principles of medical treatment and physical stimulation, with the confirmation of the fea-sibility of an integrated approach that provides effective relief of manifestations of dorsopathies. In this case, taking into account authors’ original research, attention is paid to theoretical and practical aspects of acupuncture, prescribed in the treatment of patients with dorsopathies. The authors described an effective technology pharmacopuncture, an action of which is caused by the summation of the effects of reflex irritation, actions of the drug. Based on the results of many years of personal research, the authors note that pharmacopuncture involves the use of various drugs, but just the complex homeopathic remedies provide a clear therapeutic result.


2019 ◽  
Vol 1 (1) ◽  
pp. 72-81
Author(s):  
Hamidreza Shirzadfar ◽  
Narsis Gordoghli

In recent years, chronic medical problems have become increasingly prevalent. Chronic ‎illnesses challenge the view of life as a regular and continuous process, a challenge that has ‎important psychological consequences. The long duration of people suffering from these ‎diseases, the long process of treatment and the fact that there is no proper and definitive ‎treatment for most of these diseases and their associated complications have made chronic ‎diseases a detrimental factor in public health. According to the World Health Organization ‎‎(2006), the prevalence of chronic and non-communicable diseases is increasing in all countries, ‎especially developing countries, so that the major challenge for the health system in the present ‎century, is not living people, but better adapted to chronic illnesses and maintaining their ‎mental and social health and well-being Ed's life-threatening chronic physical illness.‎ Chronic pain is a pain that lasts longer than usual, and according to the criteria of the ‎International Association of Pain, this time is defined as at least 3 months to 6 months. Chronic ‎pain is such that not only faced the sick person whit the pressure of the pain but also with many ‎other pressure that affect different parts of her life. Fibromyalgia is one of the most rheumatologic disorders and one of the most resistant chronic ‎pain syndromes. Fibromyalgia is one of the most common musculoskeletal disorders in adults ‎and chronic pain is one of the most common complaints in this group of patients.


2021 ◽  
Vol 14 (1) ◽  
pp. 71
Author(s):  
Katarzyna Kotfis ◽  
Kacper Lechowicz ◽  
Sylwester Drożdżal ◽  
Paulina Niedźwiedzka-Rystwej ◽  
Tomasz K. Wojdacz ◽  
...  

In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared a global pandemic by the World Health Organization (WHO). The clinical course of the disease is unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to acute respiratory distress syndrome (ARDS). It has been shown that pulmonary fibrosis may be one of the major long-term complications of COVID-19. In animal models, the use of spironolactone was proven to be an important drug in the prevention of pulmonary fibrosis. Through its dual action as a mineralocorticoid receptor (MR) antagonist and an androgenic inhibitor, spironolactone can provide significant benefits concerning COVID-19 infection. The primary effect of spironolactone in reducing pulmonary edema may also be beneficial in COVID-19 ARDS. Spironolactone is a well-known, widely used and safe anti-hypertensive and antiandrogenic medication. It has potassium-sparing diuretic action by antagonizing mineralocorticoid receptors (MRs). Spironolactone and potassium canrenoate, exerting combined pleiotropic action, may provide a therapeutic benefit to patients with COVID-19 pneumonia through antiandrogen, MR blocking, antifibrotic and anti-hyperinflammatory action. It has been proposed that spironolactone may prevent acute lung injury in COVID-19 infection due to its pleiotropic effects with favorable renin–angiotensin–aldosterone system (RAAS) and ACE2 expression, reduction in transmembrane serine protease 2 (TMPRSS2) activity and antiandrogenic action, and therefore it may prove to act as additional protection for patients at highest risk of severe pneumonia. Future prospective clinical trials are warranted to evaluate its therapeutic potential.


2015 ◽  
Vol 112 (47) ◽  
pp. E6525-E6534 ◽  
Author(s):  
Yunan Yang ◽  
Reinier Hernandez ◽  
Jun Rao ◽  
Li Yin ◽  
Yazhuo Qu ◽  
...  

Given the highly heterogeneous character of brain malignancies and the associated implication for its proper diagnosis and treatment, finding biomarkers that better characterize this disease from a molecular standpoint is imperative. In this study, we evaluated CD146 as a potential molecular target for diagnosis and targeted therapy of glioblastoma multiforme (GBM), the most common and lethal brain malignancy. YY146, an anti-CD146 monoclonal antibody, was generated and radiolabeled for noninvasive positron-emission tomography (PET) imaging of orthotopic GBM models. 64Cu-labeled YY146 preferentially accumulated in the tumors of mice bearing U87MG xenografts, which allowed the acquisition of high-contrast PET images of small tumor nodules (∼2 mm). Additionally, we found that tumor uptake correlated with the levels of CD146 expression in a highly specific manner. We also explored the potential therapeutic effects of YY146 on the cancer stem cell (CSC) and epithelial-to-mesenchymal (EMT) properties of U87MG cells, demonstrating that YY146 can mitigate those aggressive phenotypes. Using YY146 as the primary antibody, we performed histological studies of World Health Organization (WHO) grades I through IV primary gliomas. The positive correlation found between CD146-positive staining and high tumor grade (χ2 = 9.028; P = 0.029) concurred with the GBM data available in The Cancer Genome Atlas (TCGA) and validated the clinical value of YY146. In addition, we demonstrate that YY146 can be used to detect CD146 in various cancer cell lines and human resected tumor tissues of multiple other tumor types (gastric, ovarian, liver, and lung), indicating a broad applicability of YY146 in solid tumors.


2021 ◽  
Vol 18 (2) ◽  
pp. 4-15
Author(s):  
Luan Oliveira Silva ◽  
◽  
Leandro dos Santos Araújo ◽  
Victor Ferreira Souza ◽  
Raimundo Matos Barros Neto ◽  
...  

Pneumonia is one of the most common medical problems in clinical practice and is the leading fatal infectious disease worldwide. According to the World Health Organization, pneumonia kills about 2 million children under the age of 5 and is constantly estimated to be the leading cause of infant mortality, killing more children than AIDS, malaria, and measles combined. A key element in the diagnosis is radiographic data, as chest x-rays are routinely obtained as a standard of care and can aid to differentiate the types of pneumonia. However, a rapid radiological interpretation of images is not always available, particularly in places with few resources, where childhood pneumonia has the highest incidence and mortality rates. As an alternative, the application of deep learning techniques for the classification of medical images has grown considerably in recent years. This study presents five implementations of convolutional neural networks (CNNs): ResNet50, VGG-16, InceptionV3, InceptionResNetV2, and ResNeXt50. To support the diagnosis of the disease, these CNNs were applied to solve the classification problem of medical radiographs from people with pneumonia. InceptionResNetV2 obtained the best recall and precision results for the Normal and Pneumonia classes, 93.95% and 97.52% respectively. ResNeXt50 achieved the best precision and f1-score results for the Normal class (94.62% and 94.25% respectively) and the recall and f1-score results for the Pneumonia class (97.80% and 97.65%, respectively).


Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 2018 ◽  
Author(s):  
Francesca Salamanna ◽  
Veronica Borsari ◽  
Deyanira Contartese ◽  
Viviana Costa ◽  
Gianluca Giavaresi ◽  
...  

Breast cancer cells produce stimulators of bone resorption known as interleukins (ILs). However, data on the functional roles of ILs in the homing of metastatic breast cancer to bone are still fragmented. A systematic search was carried out in three databases (PubMed, Scopus, Web of Science Core Collection) to identify preclinical reports, and in three clinical registers (ClinicalTrials.gov, World Health Organization (WHO) International Clinical Trials Registry Platform, European Union (EU) Clinical Trials Register) to identify clinical trials, from 2008 to 2019. Sixty-seven preclinical studies and 11 clinical trials were recognized as eligible. Although preclinical studies identified specific key ILs which promote breast cancer bone metastases, which have pro-metastatic effects (e.g., IL-6, IL-8, IL-1β, IL-11), and whose inhibition also shows potential preclinical therapeutic effects, the clinical trials focused principally on ILs (IL-2 and IL-12), which have an anti-metastatic effect and a potential to generate a localized and systemic antitumor response. However, these clinical trials are yet to post any results or conclusions. This inconsistency indicates that further studies are necessary to further develop the understanding of cellular and molecular relations, as well as signaling pathways, both up- and downstream of ILs, which could represent a novel strategy to treat tumors that are resistant to standard care therapies for patients affected by breast cancer bone disease.


2008 ◽  
Vol 22 (2) ◽  
pp. 169-175 ◽  
Author(s):  
Gregor Reid ◽  
Kingsley Anukam ◽  
Tara Koyama

Probiotics, defined as ‘live microorganisms, which when administered in adequate amounts, confer a health benefit on the host’, are finally becoming an option for gastroenterologists in Canada, after being available for many years in Japan, Europe and the United States of America. Unfortunately, Health Canada and the US Food and Drug Administration have not controlled the use of the term ‘probiotic’ or put into place United Nations and World Health Organization guidelines. The net result is that a host of products called ‘probiotics’ are available but are not truly probiotic. The aim of the present review was to discuss the rationale for probiotics in gastroenterology, and specifically examine which products are options for physicians in Canada, and which ones patients might be using. It is hoped that by clarifying what probiotics are, and the strengths and limitations of their use, specialists will be better placed to make recommendations on the role of these products in patient care. In due course, more clinically documented probiotics will emerge, some with therapeutic effects based on a better understanding of disease processes.


2021 ◽  
pp. 58-60
Author(s):  
Liliia Babynets

The World Health Organization identifies hypertension (AH) as «the world’s leading global risk of increased mortality from cardiovascular disease». AH is one of the most serious health problems because of its prevalence and importance. Caring for a patient with AH with or without chronic comorbidity requires a long-term holistic, patient-centered approach. The goal of treating a patient with AH is to reduce the overall cardiovascular risk, notu jst to control blood pressure. The aim is to analyze the possibilities of basic drug therapy and control over its implementation in patients with hypertension in different clinical situations in the practice of a family physician. Newly detected AH in a patient requires careful examination and appointment of effective comprehensive treatment. The tactics of selection of antihypertensive treatment for a patient with newly diagnosed hypertension are considered on a clinical example. Improving lifestyle and healthy living habits are necessary for all patients with AH, even when antihypertensive medication is mandatory. It is important to regulate blood pressure. The choice of medication depends on the patient’s characteristics and comorbidities. Care of a patient with hypertension should be carried out holistically with the identification and control of additional risk factors and complications, in parallel with the control of hypertension. At the same time it is necessary to take care of the treatment of some other somatic diseases or mental disorders that may affect the outcome of treatment of hypertension.


Author(s):  
Chincholikar Sanjeev Vasantrao

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. It has been declared a pandemic by the World Health Organization which exhibited human-to-human transmissibility and spread rapidly across countries. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. Climate, with temperature, humidity, Bacillus Calmette–Guérin (BCG) vaccination, immune status of persons, elderly people, uncontrolled co morbid conditions like heart diseases, diabetes mellitus, hypertension, kidney diseases seems to play an important role in spread and severity of corona virus infection. As reported from MOHFW website, the COVID-19 deaths are more in above 60 years of age with comorbidities cardiovascular disease, diabetes, chronic respiratory disease, and cancer.


2020 ◽  
Vol 11 (SPL1) ◽  
pp. 385-390
Author(s):  
Dushyant Bawiskar ◽  
Pratik Phansopkar ◽  
Ayurva Vilas Gotmare

We are in the middle of an unprecedented pandemic named COVID-19 by the World Health Organization (WHO) which is caused by a novel coronavirus. The novelty of the virus and its disease is so new that the entire world is experiencing its consequences on various aspects. The pandemic is still unfolding and creating some new patterns around us. Besides the buzzword, that is, the vaccine is far from our sight. So naturally, we have to look for existing solutions if they can be implemented until the vaccine arrives. From Hydroxychloroquine (HCQ) to Bacillus Calmette Guèrin (BCG) all are being used in trials whether they can be pre-vaccine medicine or not. The variable effect on individual sections of the population has to be studied to deliver a targeted response, especially in resource lacking countries. In addition to these medical problems like social distress and quarantine measures which are taking a toll on people's minds, another unwarranted problem of Infodemic has struck us. So, this paper will review the ongoing steps and challenges and how we can efficiently respond to them to conquer this pandemic.


Sign in / Sign up

Export Citation Format

Share Document